[Bone and soft tissue sarcomas].
Great progress has been made both in the treatment of metastatic sarcomas and in adjuvant treatment of Ewing's, rhabdomyo- and osteogenic sarcomas. This is due partly to new and more effective cytostatic drugs and combinations, but to a greater extent to an improved systematic multimodal approach. In patients with metastatic sarcoma, better and longer remissions can be achieved, whereas real cures are possible in Ewing's, rhabdomyo- and osteosarcoma if properly managed using an interdisciplinary approach. Patients with these rare malignancies should be referred to specialized cancer centers, in view of the problems and possible complications of their necessarily intensive therapy.
D000368:Aged; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008017:Life Expectancy; D008727:Methotrexate / Q000627:therapeutic use; D012516:Osteosarcoma / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012512:Sarcoma, Ewing / Q000601:surgery; D012983:Soft Tissue Neoplasms / Q000628:therapy*; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate
Knochen- und Weichteilsarkome.